April 19, 2004
Neurogen Corporation, a small molecule drug discovery and development company, enters into definitive purchase agreement for the sale of $100 million of newly-issued common stock, with lead investors including Willkie client Warburg Pincus LLC.
On March 19, it was announced that Neurogen Corporation, a small molecule drug discovery and development company, has entered into a definitive purchase agreement for the sale of $100 million of newly-issued common stock at a price of $7.00 per share. The lead investors in the financing are Willkie client Warburg Pincus LLC and Baker Brothers Investments. Neurogen expects the financing to close during the second quarter. The March 22 Daily Deal reported that Willkie attorneys on the deal were partners Steven Gartner and associate Nicole Napolitano. This deal closed on April 19.